A recent study displayed that treatment of GC cells with the vitamin D receptor (VDR) ligand calcipotriol could very effectively abolish the oxaliplatin resistance of GC cells, which is mediated by inhibiting the tumor-supporting activity of CAF, suggesting that vitamin D may act as a defensive agent in GC chemotherapy [187]. Here, VDR is linked to gastric cancer.